000062451 001__ 62451
000062451 005__ 20200610183931.0
000062451 0247_ $$2Handle$$a2128/13953
000062451 037__ $$aPreJuSER-62451
000062451 0881_ $$aJuel-4273
000062451 088__ $$2JUEL$$aJuel-4273
000062451 1001_ $$0P:(DE-Juel1)VDB76321$$aWagner, Franziska M.$$b0$$eCorresponding author$$uFZJ
000062451 245__ $$aZur Synthese radiofluorierter aromatischer Aminosäuren mittels Isotopenaustausch am Beispiel von 6-[$^{18}$F]Fluor-L-DOPA
000062451 260__ $$aJülich$$bForschungszentrum Jülich GmbH Zentralbibliothek, Verlag$$c2008
000062451 300__ $$aIII, 188 p.
000062451 3367_ $$0PUB:(DE-HGF)11$$2PUB:(DE-HGF)$$aDissertation / PhD Thesis
000062451 3367_ $$0PUB:(DE-HGF)3$$2PUB:(DE-HGF)$$aBook
000062451 3367_ $$02$$2EndNote$$aThesis
000062451 3367_ $$2DRIVER$$adoctoralThesis
000062451 3367_ $$2BibTeX$$aPHDTHESIS
000062451 3367_ $$2DataCite$$aOutput Types/Dissertation
000062451 3367_ $$2ORCID$$aDISSERTATION
000062451 4900_ $$0PERI:(DE-600)2414853-2$$831012$$aBerichte des Forschungszentrums Jülich$$v4273$$x0944-2952
000062451 502__ $$aKöln, Univ., Diss., 2008$$bDr. (Univ.)$$cUniv. Köln$$d2008
000062451 500__ $$aRecord converted from VDB: 12.11.2012
000062451 520__ $$aIn nuclear medical diagnosis, 6-[$^{18}$F]fluoro-L-3,4-dihydroxyphenylalanine (6-[$^{18}$F]fluoro-LDOPA), an analogue of L-DOPA, is one of the few established radiopharmaceuticals used for the in vivo investigation of the presynaptic dopaminergic metabolism and of some kind of tumours via Positron Emission Tomography (PET). The presently used method of preparation of the radiotracer by electrophilic labelling is limited to low amounts of activity at high costs. Known nucleophilic syntheses, however, result either in insufficient enantiomeric purity or the known multi-step syntheses are hard to automate, due to their complexity. During this work a novel, easy to automate alternative for the preparation of 6-[$^{18}$F]fluoro-L-DOPA, was developed and evaluated, using a direct nucleophilic $^{18}$F-fluorination of a protected amino acid derivative. The resulting product has a very high enantiomeric purity. At first, the general suitability of the (S)-BOC-BMI-derivatives for the synthesis of $^{18}$F-labelled amino acids, used in this work, was investigated using a less complex precursor, which resulted in the amino acid 6-[$^{18}$F]fluoro-L-m-tyrosin via acidic hydrolysis. The preparation of a useful precursor for the nucleophilic $^{18}$F-isotope substitution, namely the (2S,5S)-tert.-butyl-5-(2-fluoro-5-formylbenzyl)-2-tert.-butyl-3-methyl-4-oxoimidazolidine-1-carboxylate, was investigated in three general different ways. At first it was tried to obtain this product via formylation after coupling with the BOC-BMI, secondly via a,b-dehydro amino acid derivatives and finally via a systematic multi-step synthesis. Only the last mentioned way resulted in a precursor with sufficient purity that could be labelled. The radiochemical yield of the isotopic exchange was about 60 %. In the next step, the presented concept was modified to synthesize a precursor for the preparation of 6-[$^{18}$F]fluoro-L-DOPA. Only a combination of the protecting groups benzyl and THP resulted in the useful precursor (2S,5S)-tert.-butyl-5-(4-benzyloxy-2-fluoro-5-formylbenzyl)-2-tert.-butyl-3-methyl-4-oxoimidazolidine-1-carboxylate. By optimisation of the isotopic exchange with [18F]fluoride on this precursor a radiochemical yield of about 50 % was achieved. After a three step synthesis including the labelling, a Baeyer-Villiger-oxidation using mCPBA and a hydrolysis using HBr, c.a. 6-[$^{18}$F]fluoro-L-DOPA was isolated containing more than 99 % of the desired L-isomer. The complete preparation and isolation of c.a. 6-[$^{18}$F]fluoro-L-DOPA, using optimised conditions, resulted in a decay corrected yield of about 22 % after a synthesis time of 105 minutes. Thus the presented synthesis of 6-[$^{18}$F]fluoro-L-DOPA is not only more efficient than the known methods of preparation, but is furthermore fully automatable.
000062451 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems$$cP33$$x0
000062451 655_7 $$aHochschulschrift$$xDissertation (Univ.)
000062451 8564_ $$uhttps://juser.fz-juelich.de/record/62451/files/J%C3%BCl_4273_Wagner.pdf$$yOpenAccess
000062451 909CO $$ooai:juser.fz-juelich.de:62451$$pdnbdelivery$$pVDB$$pdriver$$popen_access$$popenaire
000062451 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000062451 9141_ $$y2008
000062451 9131_ $$0G:(DE-Juel1)FUEK409$$bGesundheit$$kP33$$lFunktion und Dysfunktion des Nervensystems$$vFunktion und Dysfunktion des Nervensystems$$x0
000062451 9201_ $$0I:(DE-Juel1)VDB807$$d31.12.2008$$gINB$$kINB-4$$lNuklearchemie$$x0
000062451 970__ $$aVDB:(DE-Juel1)98792
000062451 980__ $$aVDB
000062451 980__ $$aConvertedRecord
000062451 980__ $$aphd
000062451 980__ $$aI:(DE-Juel1)INM-5-20090406
000062451 980__ $$aUNRESTRICTED
000062451 9801_ $$aFullTexts
000062451 981__ $$aI:(DE-Juel1)INM-5-20090406